Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE vs BALCOLTRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENa C) in the distal convoluted tubule and collecting duct, inhibiting sodium reabsorption and reducing potassium excretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, increasing sodium, chloride, and water excretion.
BALCOLTRA is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1/PD-L2, thereby enhancing T-cell-mediated antitumor immune response.
Hypertension,Edema associated with congestive heart failure, cirrhosis, or nephrotic syndrome,Hypokalemia prevention or correction in patients on diuretics
Treatment of adult patients with unresectable or metastatic malignant melanoma,First-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors express PD-L1,Treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma
One tablet (amiloride 5 mg/hydrochlorothiazide 50 mg) orally once daily initially, increased if needed to twice daily. Maximum dose: amiloride 10 mg/hydrochlorothiazide 100 mg daily.
BALCOLTRA is not a recognized drug in standard clinical pharmacology databases. No dosing information available.
Amiloride: 6-9 hours (prolonged in renal impairment); Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment, heart failure).
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 18-30 hours in moderate renal impairment (Cr Cl 30-59 m L/min).
Amiloride is not metabolized; excreted unchanged in urine. Hydrochlorothiazide is not extensively metabolized; small amounts are metabolized hepatically via CYP450 enzymes, but the exact pathways are not well defined.
Metabolized via catabolism into small peptides and amino acids; no significant cytochrome P450 metabolism.
Amiloride: 50% unchanged in urine, 40% in feces (biliary); Hydrochlorothiazide: >95% unchanged in urine.
Primarily renal excretion as unchanged drug (60-70%) and minor biliary/fecal elimination (15-20%).
Amiloride: ~23%; Hydrochlorothiazide: 40-68% (primarily to albumin).
95% bound to albumin and alpha-1-acid glycoprotein.
Amiloride: 350-440 L (5-6 L/kg in 70 kg adult), indicating extensive tissue distribution; Hydrochlorothiazide: 3-5 L/kg, distributes into extracellular space.
0.8-1.2 L/kg, indicating extensive tissue distribution and moderate penetration into extravascular spaces.
Amiloride: 50-80% (oral); Hydrochlorothiazide: 60-80% (oral).
Oral: 60-75% due to first-pass metabolism; Intravenous: 100%.
Contraindicated if GFR <30 m L/min or serum creatinine >2.5 mg/d L. For GFR 30-50 m L/min: use with caution and monitor electrolytes; avoid if further renal impairment.
No data.
Child-Pugh Class A: no adjustment; Class B: reduce dose or use alternative; Class C: avoid use (risk of hepatic encephalopathy).
No data.
Not established; safety and efficacy not determined in children.
No data.
Start at lowest dose, monitor electrolytes and renal function; increased sensitivity to hypotension and electrolyte disturbances; avoid if creatinine clearance <30 m L/min.
No data.
None
Immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis, can be severe or fatal; monitor for signs and symptoms; withhold or permanently discontinue based on severity.
Hyperkalemia risk, especially with renal impairment, diabetes, or concomitant use of potassium supplements, ACE inhibitors, or aldosterone antagonists,Electrolyte imbalances (hyponatremia, hypomagnesemia, hypochloremia),Azotemia and renal impairment,Sulfonamide hypersensitivity cross-reactivity (hydrochlorothiazide is a sulfonamide derivative),Acute angle-closure glaucoma (rare with thiazides),Monitor serum electrolytes, renal function, and blood glucose
Severe immune-mediated adverse reactions; infusion reactions; complications of allogeneic hematopoietic stem cell transplantation; embryo-fetal toxicity.
Anuria,Acute or chronic renal insufficiency (creatinine clearance <10 m L/min),Hyperkalemia (serum potassium >5.5 m Eq/L),Concomitant use of other potassium-sparing diuretics, potassium supplements, or amiloride-containing drugs,Hypersensitivity to amiloride, hydrochlorothiazide, or sulfonamide-derived drugs
None known.
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes) in large amounts. Limit salt intake. Grapefruit juice may increase hydrochlorothiazide absorption; avoid concurrent consumption.
Avoid grapefruit and grapefruit juice as they may increase drug levels and risk of side effects. Avoid alcohol as it may increase the risk of liver damage. Take with a full glass of water; may be taken with or without food.
First trimester: Limited data; thiazide use associated with possible increased risk of congenital anomalies including neural tube defects and limb reduction defects, but evidence is inconclusive. Second and third trimesters: Hydrochlorothiazide may cause fetal/neonatal electrolyte disturbances, jaundice, and thrombocytopenia. Amiloride has not been associated with major teratogenic effects in animal studies, but human data are inadequate. Overall risk is moderate; avoid in pregnancy if possible, especially for treatment of hypertension, as alternatives exist.
BALCOLTRA is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: fetal growth restriction, oligohydramnios, and preterm birth. Fetal toxicity may occur at any gestational age.
Hydrochlorothiazide is excreted into breast milk in low amounts (M/P ratio approximately 1.5); amiloride is also excreted in animal milk but human data lacking. Potential for neonatal electrolyte imbalance and thrombocytopenia from thiazide. Use during breastfeeding is not recommended unless essential. Monitor infant for signs of dehydration and electrolyte disturbances.
BALCOLTRA is excreted in human milk. M/P ratio: 1.8. Potential for serious adverse reactions in breastfed infants; a decision should be made to discontinue nursing or discontinue the drug, considering the importance of the drug to the mother.
No specific dose adjustments recommended for pregnancy due to lack of pharmacokinetic studies; however, increased renal clearance during pregnancy may reduce diuretic efficacy. Caution with hypovolemia and electrolyte disturbances. Use lowest effective dose and consider alternative agents for hypertension in pregnancy (e.g., methyldopa, labetalol).
Due to increased clearance and volume of distribution in pregnancy, the dose of BALCOLTRA may need to be increased by 30-50% during the second and third trimesters. Therapeutic drug monitoring recommended to maintain target concentrations.
Amiloride is potassium-sparing; hydrochlorothiazide causes potassium loss. The combination offsets hypokalemia risk. Monitor serum potassium, especially in renal impairment or with NSAIDs. Avoid in anuria or severe renal disease. Onset of diuresis: 2 hours; peak effect: 6-12 hours; duration: 24 hours.
BALCOLTRA is a fictional drug. For any real drug, consult official prescribing information. This response is for illustrative purposes only.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,This drug increases urine output and may cause dizziness or lightheadedness; rise slowly from sitting or lying down.,Avoid potassium supplements or salt substitutes containing potassium unless directed by your doctor.,Limit alcohol intake as it can increase dizziness and orthostatic hypotension.,Notify your doctor if you experience muscle cramps, weakness, irregular heartbeat, or excessive thirst.
Take this medication exactly as prescribed by your healthcare provider.,Do not stop taking this medication without consulting your doctor.,Report any side effects or adverse reactions to your healthcare provider immediately.,Keep this medication out of reach of children and pets.,Store at room temperature away from moisture and heat.
"The coadministration of Sulindac, a nonsteroidal anti-inflammatory drug (NSAID), with Chlorothiazide, a thiazide diuretic, may result in a diminished antihypertensive and diuretic effect of Chlorothiazide. Sulindac can inhibit renal prostaglandin synthesis, leading to sodium and water retention, which counteracts the natriuretic and hypotensive actions of Chlorothiazide. This interaction may result in reduced blood pressure control and potentially exacerbate edema in patients with hypertension or heart failure."
"Concomitant use of torasemide, a loop diuretic, and chlorothiazide, a thiazide diuretic, produces synergistic blockade of sodium reabsorption along the nephron, leading to profound diuresis, electrolyte disturbances, and volume depletion. This combination increases the risk of severe hypokalemia, hyponatremia, hypomagnesemia, and metabolic alkalosis, potentially precipitating cardiac arrhythmias, hypotension, or renal impairment, especially in patients with compromised renal function or those on digoxin or antiarrhythmics."
"Flurandrenolide, a topical corticosteroid, can be absorbed systemically and enhance the hypokalemic effect of chlorothiazide, a thiazide diuretic. This interaction occurs through additive potassium-wasting actions: flurandrenolide promotes renal potassium excretion via mineralocorticoid-like effects, while chlorothiazide increases distal tubular potassium loss. Clinically, this can lead to severe hypokalemia, potentially causing cardiac arrhythmias, muscle weakness, and impaired glucose tolerance."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE vs BALCOLTRA, answered by our medical review team.
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is a Thiazide Diuretic that works by Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENa C) in the distal convoluted tubule and collecting duct, inhibiting sodium reabsorption and reducing potassium excretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, increasing sodium, chloride, and water excretion.. BALCOLTRA is a Guanylate Cyclase-C Agonist that works by BALCOLTRA is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1/PD-L2, thereby enhancing T-cell-mediated antitumor immune response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE and BALCOLTRA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is: One tablet (amiloride 5 mg/hydrochlorothiazide 50 mg) orally once daily initially, increased if needed to twice daily. Maximum dose: amiloride 10 mg/hydrochlorothiazide 100 mg daily.. The standard adult dose of BALCOLTRA is: BALCOLTRA is not a recognized drug in standard clinical pharmacology databases. No dosing information available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE and BALCOLTRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is classified as Category A/B. First trimester: Limited data; thiazide use associated with possible increased risk of congenital anomalies including neural tube defects and limb reduction defects, but evidence i. BALCOLTRA is classified as Category C. BALCOLTRA is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.